CIC Cochin Pasteur, Hôpital Cochin Port-Royal, AP-HP, Université de Paris Cité, Paris, France.
Service de Maladies Infectieuses et Tropicales, Hôpital Avicenne, AP-HP, Bobigny, France.
Clin Infect Dis. 2023 Dec 15;77(12):1648-1655. doi: 10.1093/cid/ciad603.
In the context of the circulation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta) variant, vaccination re-authorized mass indoor gatherings. The "Indoor Transmission of coronavirus disease 2019 (COVID-19)" (ITOC) trial (ClinicalTrials.gov, NCT05311865) aimed to assess the risk of transmission of SARS-CoV-2 and other respiratory viruses during an indoor clubbing event among participants fully vaccinated against COVID-19.
ITOC, a randomized controlled trial in the Paris region (France), enrolled healthy volunteers aged 18-49 years, fully vaccinated against COVID-19, with no comorbidities or symptoms, randomized 1:1 to be interventional group "attendees" or control "non-attendees." The intervention was a 7-hour indoor event in a nightclub at full capacity, with no masking, prior SARS-CoV-2 test result, or social distancing required. The primary outcome measure was the number of reverse transcriptase-polymerase chain reaction (RT-PCR)-determined SARS-CoV-2-positive subjects using self-collected saliva 7 days post-gathering in the per-protocol population. Secondary endpoints focused on 20 other respiratory viruses.
Healthy participants (n = 1216) randomized 2:1 by blocks up to 10 815 attendees and 401 non-attendees, yielding 529 and 287 subjects, respectively, with day-7 saliva samples. One day-7 sample from each group was positive. Looking at all respiratory viruses together, the clubbing event was associated with an increased risk of infection of 1.59 (95% CI, 1.04-2.61).
In the context of low Delta variant of concern circulation, no evidence of SARS-CoV-2 transmission among asymptomatic and vaccinated participants was found, but the risk of other respiratory virus transmission was higher. Clinical Trials Registration. ClinicalTrials.gov, NCT05311865.
在严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) B.1.617.2 (德尔塔)变异株流行的情况下,疫苗重新授权大规模室内聚集活动。“2019 年冠状病毒病 (COVID-19) 室内传播” (ITOC) 试验 (ClinicalTrials.gov,NCT05311865) 旨在评估完全接种 COVID-19 疫苗的参与者在室内俱乐部活动中 SARS-CoV-2 和其他呼吸道病毒传播的风险。
ITOC 是法国巴黎地区的一项随机对照试验,招募了年龄在 18-49 岁之间、完全接种 COVID-19 疫苗、无合并症或症状的健康志愿者,按 1:1 比例随机分为干预组“参加者”或对照组“不参加者”。干预措施是在一家夜总会进行 7 小时的室内活动,不戴口罩,不要求提供 SARS-CoV-2 检测结果或保持社交距离。主要结局测量指标是在方案人群中,通过自我采集唾液在聚会后 7 天内用逆转录-聚合酶链反应 (RT-PCR) 确定的 SARS-CoV-2 阳性受试者数量。次要终点集中在 20 种其他呼吸道病毒上。
按块随机分配 2:1 的健康参与者 (n = 1216) 参加了多达 10815 名参加者和 401 名不参加者的活动,分别产生了 529 名和 287 名有第 7 天唾液样本的受试者。每组各有一个第 7 天的样本呈阳性。综合所有呼吸道病毒,俱乐部活动与感染风险增加 1.59 倍(95%CI,1.04-2.61)相关。
在低关注的德尔塔变异株流行的情况下,未发现无症状和接种疫苗的参与者之间有 SARS-CoV-2 传播的证据,但其他呼吸道病毒传播的风险更高。临床试验注册。ClinicalTrials.gov,NCT05311865。